АТОРВАСТАТИН — 20 ЛЕТ В БОРЬБЕ ЗА ЖИЗНЬ
https://doi.org/10.15829/1560-4071-2018-2-134-149
Аннотация
Обсуждается эффективность и безопасность аторвастатина в снижении риска развития сердечно-сосудистых осложнений.
Ключевые слова
При поддержке: Пфайзер, компания
Об авторе
Н. Г. Гоголашвили
НИИ медицинских проблем Севера — обособленное подразделение ФИЦ КНЦ СО РАН; ФГБОУ ВО КрасГМУ им. проф. Ф.В. Войно-Ясенецкого МЗ РФ
Россия
Россия
Доктор медицинских наук, главный научный сотрудник, заведующий кардиологическим отделением клиники; профессор кафедры кардиологии и функциональной диагностики.
Красноярск
Список литературы
1. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesteroleamia by atorvastatin, a new HMG-Ko-A reductase inhibitor. Arteriosclerosis Thromb Vascular Biology 1995; 15: 678-682. DOI:10.1161/01.ATV.15.5.678.
2. Jones P, Kafonek, Laurora I, Hunninghake D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiology 1998: 81 (5): 582-7. DOI: 10.1016/S0002-9149(97)00965-X.
3. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Ther. 2000; 5 (1): 27-32. DOI: 10.1177/107424840000500104.
4. Olsson AG, Eriksson M, Johnson O, et al. A 52-week, multicenter, randomized, parallelgroup, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching lowdensity lipoprotein cholesterol and triglyceride targets: The Treat-to-Target (3T) study. Clinical Therapeutics 2003; 25 (1): 119-38. DOI: 10.1016/S0149-2918(03)90015-4.
5. Pedersen TR, Faergeman O, Kastelein JJP, et al. High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005; 294 (19): 2437-45. DOI: 10.1001/jama.294.19.2437.
6. Karalis DG, Ross AM, Vacari RM, et al. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002; 89 (6): 667-71. DOI: 10.1016/S0002-9149(01)02337-2.
7. Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia — Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 2006; 7: 35. DOI: 10.1186/1745-6215-7-35.
8. Berne C, Siewert-Delle A and URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005; 4: 7. DOI: 10.1186/1475-2840-4-7.
9. Schuster H, Barter P, Stender S, et al. MERCURI 1 Study Group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rozuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-12. DOI: 10.1016/j.ahj.2003.10.004.
10. Ballantyne СМ, Bertolami M, Hemandez Carcia HR, et al. Achieving LDL cholesterol, non–HDL cholesterol, and apolipoprotein B target levels in high–risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY II). Am Heart J 2006; 151: 975. e1-e9. DOI: 10.1016/j.ahj.2005.12.013.
11. Leiter LA, Rosenson RS, Stein E et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 2007; 194: e154-64. DOI: 10.1016/j. atherosclerosis.2006.12.001.
12. Jones PH, Davidson MH, Stein E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60. DOI: 10.1016/S0002-9149(03)00530-7.
13. McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689-98. DOI: 10.1185/030079903125002405.
14. van Himbergen Т, Matthan NR, Resteghini N, et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res. 2009; 50 (4): 730-9. DOI: 10.1194/jlr.P800042-JLR200.
15. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003; 326 (7404): 1423. DOI: 10.1136/bmj.326.7404.1423.
16. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010; 35 (2): 139-51. DOI: 10.1111/j.1365-2710.2009.01085.x.
17. Karlson BW, Palmer MK, Nicholls SJ et al. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER metaanalysis. Eur J Prev Cardiol. 2016; 23 (7): 744-7. DOI: 10.1177/2047487315598710.
18. Karlson BW, Palmer MK, Nicholls SJ, et al. Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. Atherosclerosis. 2017; 265: 54-9. DOI: 10.1016/j.atherosclerosis.2017.08.014.
19. Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015; (3): CD008226. DOI: 10.1002/14651858.CD008226.pub3.
20. Stone NJ, Robinson JG, Lichtenstein AH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129 (25 Suppl 2): S1-45. DOI: 10.1161/01.cir.0000437738.63853.7a.
21. Catapano AL, Graham I, De Backer G, et al. Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37 (39): 2999-3058. DOI: 10.1093/eurheartj/ehw272.
22. Stalenhoef AF, Ballantyne CM, Sarti C, et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. Eur Heart J 2005; 26: 2664-72. DOI: 10.1093/eurheartj/ehi482.
23. Betteridge DJ, Gibson JM, Sager PT. Comparison of Effectiveness of Rosuvastatin Versus Atorvastatin on the Achievement of Combined C-Reactive Protein (<2 mg/L) and LowDensity Lipoprotein Cholesterol (<70 mg/dl) Targets in Patients With Type 2 Diabetes Mellitus (from the ANDROMEDA Study). Am. J Cardiol 2007; 100 (8): 1245-48. DOI: 10.1016/j.amjcard.2007.05.044.
24. Sindhu S, Singh K, Salman M, et al. Effects of atorvastatin and rosuvastatin on highsensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients. J Pharmacol Pharmacother. 2011; 2 (4): 261-5. DOI: 10.4103/0976-500X.85954.
25. Qu HY, Xiao YW, Jiang GH, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in pacients with hypercholesterolemia. Pharm Res. 2009; 26 (4): 958-64. DOI: 10.1007/s11095-008-9798-6.
26. Thongtang N, Otokozawa S, Himbergen TV, et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol. 2011; 107 (3): 387-92. DOI: 10.1016/j.amjcard.2010.09.031.
27. Bonnet J, McPherson R, Tedgui A, et al. CAP Investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative AtorvastatinPleiotropic effects) study. Clin Ther. 2008; 30 (12): 2298-313. DOI: 10.1016/j.clinthera.2008.12.023.
28. Liu Z, Joerg H, Hao H, et al. Efficacy of High-Intensity Atorvastatin for Asian Patients Undergoing Percutaneous Coronary Intervention. Ann Pharmacother. 2016; 50 (9): 72533. DOI: 10.1177/1060028016654722.
29. Liu Z, Xu Y, Hao H, et al. Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus. Int J Cardiol. 2016; 222: 22-6. DOI: 10.1016/j.ijcard.2016.07.140.
30. Qu Y, Wei L, Zhang H. Inhibition of inflammation mediates the protective effect of atorvastatin reload in patients with coronary artery disease undergoing noncardiac emergency surgery. Coron Artery Dis. 2014; 25 (8): 678-84. DOI: 10.1097/MCA.0000000000000143.
31. Gavazzoni M, Gorga E, Derosa G, et al. High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. Drug Des Devel Ther. 2017; 11: 3425-34. DOI: 10.2147/DDDT.S135173.
32. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol. 2010; 8: 63844. DOI: 10.2174/157016110792006950.
33. Upala S, Wirunsawanya K, Jaruvongvanich V, Sanguankeo A. Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial. Int J Cardiol. 2017; 227: 338-41. DOI: 10.1016/j.ijcard.2016.11.073.
34. Orr JS, Dengo AL, Rivero JM, Davy KP. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension. 2009; 54: 763-8. DOI: 10.1161/HYPERTENSIONAHA.109.138248.
35. Wang J, Xu J, Zhou C, et al. Improvement of arterial stiffness by reducing oxidative stress damage in elderly hypertensive patients after 6 months of atorvastatin therapy. J Clin Hypertens (Greenwich). 2012; 14 (4): 245-9. DOI: 10.1111/j.1751-7176.2012.00600.x.
36. Kanaki AI, Sarafidis PA, Georgianos PI, et al. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens. 2013; 26 (5): 608-16. DOI: 10.1093/ajh/hps09.
37. Davenport C, Ashley DT, O’Sullivan EP, et al. The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes. J Diabetes Res. 2015; 2015: 846807. DOI: 10.1155/2015/846807.
38. Castejon R, Castañeda A, Sollet A, et al. Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity. Lupus. 2017; 26 (4): 355-64. DOI: 10.1177/0961203316662719.
39. Tuchkov AA, Gogolashvili NG, Yaskevich RA. Especially the influence of short — term therapy with high doses of statins on characteristics of the pulse wave in elderly patients with coronary artery disease. Clinical Gerontology 2017; 23 (9-10): 68-70. (In Russ.) Тучков А. А., Гоголашвили Н. Г., Яскевич Р. А. Особенности влияние кратковременной терапии высокими дозами статинов на характеристики пульсовой волны у пожилых больных с ИБС. Клиническая геронтология 2017; 23 (9-10): 68-70.
40. Tang X, Yang Y, Luo S, et al. The effect of statin therapy on plaque regression following acute coronary syndrome: a meta-analysis of prospective trials. Coron Artery Dis. 2016; 27 (8): 636-49. DOI: 10.1097/MCA.0000000000000403.
41. Okazaki S, Yokoyama T, Miyauchi K, et al. Early Statin Treatment in Patients With Acute Coronary Syndrome. Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation 2004; 110: 1061-8. 29. DOI: 10.1161/01.CIR.0000140261.58966.A4.
42. Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. 2014; 64 (21): 2207-17. DOI: 10.1016/j.jacc.2014.08.045.
43. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81. DOI: 10.1016/S0140-6736(00)04053-8.
44. Nissen S, Tuzcu M, Schoenhagen P, et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004; 291 (9): 1071-80. DOI: 10.1001/jama.291.9.1071.
45. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol. 2005; 96 (5A): 61F-68F. DOI: 10.1016/j.amjcard.2005.07.013.
46. Nicholls SJ, Ballantyne СМ, Barter PhJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365: 2078-87. DOI: 10.1056/NEJMoa1110874.
47. Matsushita K, Hibi K, Komura N et al. Effects of 4 Statins on Regression of Coronary Plaque in Acute Coronary Syndrome. Circ J. 2016; 80 (7): 1634-43. DOI: 10.1253/circj.CJ-151379.
48. Gogolashvili NG. Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine. Kardiologia. 2012; 51 (7): 84-92. (In Russ.) Гоголашвили НГ. Аторвастатин или розувастатин? Выбор с позиции доказательной медицины. Кардиология 2012; 51 (7): 84-92.
49. DiNicolantonio JJ, Lavie CJ, Serebruany VL, O’Keefe JH. Statin wars: the heavyweight match — atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med. 2013; 125 (1): 7-16. DOI: 10.3810/pgm.2013.01.2620.
50. Sever PS, Dahlöf B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens. 2001; 19 (6): 1139-47.
51. Sever PS, Dahlöf B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58. DOI: 10.1016/S0140-6736(03)12948-0.
52. Sever PS, Poulter NR, Dahlof B, et al. Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial– Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol 2005; 96: 39F-44F. DOI: 10.1016/j.amjcard.2005.06.025.
53. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 68596. DOI: 10.1016/S0140-6736(04)16895-5.
54. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8. DOI: 10.1001/jama.285.13.1711.
55. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction.Circulation 2002; 106: 1690-5. DOI: 10.1161/01.CIR.0000031568.40630.1C.
56. Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. N Engl J Med. 2004; 350 (15): 1495-504. DOI: 10.1056/NEJMoa040583.
57. Shehata M, Samir A, Dardiri M. Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients. J Interv Cardiol. 2017; 30 (6): 514-521. DOI: 10.1111/joic.12427.
58. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-8.
59. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004; 20 (5): 627-37.
60. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. The ALLIANCE study. J Am Coll Cardiol 2004; 44: 1772-9. DOI: 10.1016/j.jacc.2004.07.053.
61. Waters DD, Guyton JR, Herrington DM, et al. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93: 154-8. DOI: 10.1016/j.amjcard.2003.09.031.
62. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352 (14): 1425-35. DOI: 10.1056/NEJMoa050461.
63. Gogolashvili NG. Statins and percutaneous coronary intervention. Focus on atorvastatin. Rational Pharmacotherapy in Cardiology. 2014; 10 (4): 438-43. (In Russ.) Гоголашвили НГ. Статины и чрескожные коронарные вмешательства. Фокус на аторвастатин. Рациональная Фармакотерапия в Кардиологии 2014; 10 (4): 438-43.
64. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-8. DOI: 10.1161/01.CIR.0000137828.06205.87.
65. Testa L, Van Gaal WJ, Biondi Zoccai GG, et al. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 2009; 102 (6): 369-78. DOI: 10.1093/qjmed/hcp005.
66. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (NAPLES) II trial impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54: 2157-63. DOI: 10.1016/j.jacc.2009.07.005.
67. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA- ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-8. DOI: 10.1016/j.jacc.2007.02.025.
68. Briguori C, Quintavalle C, D’Alessio F, et al. Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. Int J Cardiol. 2017; 244: 112-8. DOI: 10.1016/j.ijcard.2017.06.087.
69. Liu W, Zou Z, Jiang H, et al. Clinical effect of preoperative high-dose atorvastatin against no-reflow after PCI. Exp Ther Med. 2017; 13 (1): 97-102. DOI: 10.3892/etm.2016.3910.
70. Sardella G, Lucisano L, Mancone M, et al. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial. Int J Cardiol. 2013; 168 (4): 371520. DOI: 10.1016/j.ijcard.2013.06.017.
71. Im E, Cho YH, Suh Y, et al. High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study. Rev Esp Cardiol (Engl Ed). 2017. pii: S1885-5857(17)30317-1. DOI: 10.1016/j.rec.2017.06.008.
72. Lu C, Jia H, Wang Z. High-dose atorvastatin reduces the risk of cardiovascular events in patients with percutaneous coronary intervention. Oncotarget. 2017; 8 (41): 70356-65. DOI: 10.18632/oncotarget.19701.
73. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA- 3 study. Circulation 2006; 114: 1455-61. DOI: 10.1161/CIRCULATIONAHA.106.621763.
74. Tsai YT, Lai CH, Loh SH, et al. Assessment of the Risk Factors and Outcomes for Postoperative Atrial Fibrillation Patients Undergoing Isolated Coronary Artery Bypass Grafting. Acta Cardiol Sin. 2015; 31 (5): 436-43. DOI: 10.6515/ACS20150609A.
75. Todorov H, Janssen I, Honndorf S, et al. Clinical significance and risk factors for new onset and recurring atrial fibrillation following cardiac surgery — a retrospective data analysis. BMC Anesthesiol. 2017; 17 (1): 163. DOI: 10.1186/s12871-017-0455-7.
76. Kuhn EW, Slottosch I, Wahlers T, Liakopoulos OJ. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev. 2015; 8: CD008493. DOI: 10.1002/14651858.CD008493.pub3.
77. Elgendy IY, Mahmoud A, Huo T, et al. Meta-analysis of 12 trials evaluating the effects of statins on decreasing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2015; 115 (11): 1523-8. DOI: 10.1016/j.amjcard.2015.02.053.
78. Yuan X, Du J, Liu Q, Zhang L. Defining the role of perioperative statin treatment in patients after cardiac surgery: A meta-analysis and systematic review of 20 randomized controlled trials. Int J Cardiol. 2017; 228: 958-66. DOI: 10.1016/j.ijcard.2016.11.116.
79. Nenna A, Lusini M, Spadaccio C, et al. Preoperative atorvastatin reduces bleeding and blood products use in patients undergoing on-pump coronary artery bypass grafting. J Cardiovasc Med (Hagerstown). 2017; 18 (12): 976-82. DOI: 10.2459/JCM.0000000000000550.
80. Xia J, Qu Y, Shen H, Liu X. Patients with stable coronary artery disease receiving chronic statin treatment who are undergoing noncardiac emergency surgery benefit from acute atorvastatin reloa. Cardiology. 2014; 128 (3): 285-92. DOI: 10.1159/000362593.
81. Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-9. DOI: 10.1016/S0140-6736(08)61240-4.
82. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61. DOI: 10.1056/NEJMoa0706201.
83. Rogers JK, Jhund PS, Perez AC, et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail 2014; 2: 289-97. DOI: 10.1016/j.jchf.2013.12.007.
84. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail. 2008; 14: 140-4. DOI: 10.1016/j.cardfail.2007.10.013.
85. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007; 115 (5): 576-83. DOI: 10.1161/CIRCULATIONAHA.106.625574.
86. Strandberg TE, Holme I, Faergeman O, et al. IDEAL Study Group. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. Am J Cardiol. 2009; 103 (10): 1381-5. DOI: 10.1016/j.amjcard.2009.01.377.
87. Duan HY, Liu DM, Qian P, et al. Effect of atorvastatin on plasma NT-proBNP and inflammatory cytokine expression in patients with heart failure. Genet Mol Res. 2015; 14 (4): 15739-48. DOI: 10.4238/2015.December.1.25.
88. Grishaev SL, Filippov AE, Obrezan AG, et al. Effect of atorvastatin therapy on the clinical course of chronic heart failure of non-ischemic origin. Vestnik SPbSU.Series 11. Medicine, 2016; issue 4: 15-25. (In Russ.) Гришаев С Л, Филиппов А Е, Обрезан АГ и соавт. Влияние терапии аторвастатином на клиническое течение хронической сердечной недостаточности неишемического генеза. Вестник СПбГУ. Серия 11. Медицина. 2016; 4: 15-25. DOI: 10.21638/11701/spbu11.2016.402.
89. Xu M, Yuan G, Wei F. Effect of atorvastatin in patients with chronic heart failure — insights from randomized clinical trials. Arch Med Sci. 2010; 6 (6): 866-73. DOI: 10.5114/aoms.2010.19293.
90. Wang JQ, Wu GR, Wang Z, et al. Long-term Clinical Outcomes of Statin Use for Chronic Heart Failure: A Meta-analysis of 15 Prospective Studies. Heart Lung Circ. 2014; 23 (2): 105-13. DOI: 10.1016/j.hlc.2013.07.012.
91. Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J. 2015; 36 (24): 1536-46. DOI: 10.1093/eurheartj/ehv072.
92. Westman PC, Lipinski MJ. The use of statins in patients with heart failure: more questions than answers. J Thorac Dis. 2015; 7 (10): 1687-90. DOI: 10.3978/j.issn.20721439.2015.10.47.
93. Liu G, Zheng XX, Xu YL, et al. Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials. Heart Lung Circ. 2014; 23 (10): 970-7. DOI: 10.1016/j.hlc.2014.05.005.
94. Bonsu KO, Reidpath DD, Kadirvelu A. Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials. Cardiovasc Ther. 2015; 33 (6): 338-46. DOI: 10.1111/17555922.12150.
95. Bonsu KO, Reidpath DD, Kadirvelu A. Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials. Cardiovasc Drugs Ther. 2016; 30 (2): 177-88. DOI: 10.1007/s10557015-6636-z.
96. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack.N Engl J Med. 2006; 355 (6): 549-59. DOI: 10.1056/NEJMoa061894.
97. Zhong P, Wu D, Ye X, et al. Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis. Drug Des Devel Ther. 2017; 11: 2517-26. DOI: 10.2147/DDDT.S135785.
98. Foley TR, Singh GD, Kokkinidis DG, et al. High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. J Am Heart Assoc. 2017; 15; 6 (7). pii: e005699. DOI: 10.1161/JAHA.117.005699.
99. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351 (13): 1296-305. DOI: 10.1056/NEJMoa041031.
100. Masoudi FA, Plomondon ME, Magid DJ, et al. Renal insufficiency and mortality from acute coronary syndromes. Am Heart J 2004; 147 (4): 623-29. DOI: 10.1016/j.ahj.2003.12.010.
101. Nikolic D, Banach M, Nikfar S, et al. Lipid and Blood Pressure Meta-Analysis Collaboration Group. A meta-analysis of the role of statins on renal outcomes in patientswith chronic kidney disease. Is the duration of therapy important? Int J Cardiol. 2013; 168 (6): 5437-47. DOI: 10.1016/j.ijcard.2013.08.060.
102. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157 (4): 263-75. DOI: 10.7326/0003-4819-157-4-201208210-00007.
103. Gogolashvili NG. Safety issues of atorvastatin usage in patients with a chronic kidney disease. Journal of Aterosclerosis and dyslipidamias 2016; 24 (3): 15-30. (In Russ.) Гоголашвили НГ Вопросы безопасности аторвастатина у больных с хронической болезнью почек. Атеросклероз и дислипидемии. 2016; 24 (3): 15-30.
104. ИНСТРУКЦИЯ по медицинскому применению препарата ЛИПРИМАР® П N014014/01.https://www.pfizer.ru/products/allproducts
105. Cardiovascular risk and chronic kidney disease: cardio — nephroprotection strategies. Recommendations by the Joint Expert Committee of the Russian Society of Cardiology (RSC), the Scientific Society of Russian Nephrologists (SSRN), the Russian Association of Endocrinologists (RAE), the Russian Society of Hypertension (RSH), the Russian National Atherosclerosis Society (RNAS), and the Russian Scientific Society of Internal Medicine (RSSIM) Moiseev VS, Mukhin NA, Smirnov AV et al. Russian Journal of Cardiology 2014; 8 (112): 7-37. (In Russ.) Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Клинические рекомендации. Моисеев BC, Мухин НА, Смирнов АВ и соавт. Российский кардиологический журнал. 2014; 8 (112): 7-37. DOI: 10.15829/1560-4071-2014-8-7-37.
106. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54 (5): 810-9. DOI: 10.1053/j.ajkd.2009.03.022.
107. Amarenco P, Callahan A3rd, Campese VM, et al. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014; 45 (10): 2974-82. DOI: 10.1161/STROKEAHA.114.005832.
108. Shepherd J, Kastelein JJ, Bittner V, et al. Treating to New Targets Investigators. Intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol 2007; 2 (6): 1131-9. DOI: 10.2215/CJN.04371206.
109. de Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015; 3 (3): 181-90. DOI: 10.1016/S22138587(14)70246-3.
110. Takagi H, Umemoto T. A meta-analysis of randomized trials for effects of atorvastatin on renal function inchronic kidney disease. Int J Cardiol. 2011; 152 (2): 242-4. DOI: 10.1016/j.ijcard.2011.06.107.
111. Wu Y, Wang Y, An C, et al. Effects of rosuvastatin and atorvastatin on renal function: metaanalysis. Circ J. 2012; 76 (5): 1259-66. DOI: 10.1253/circj.CJ-11-1385.
112. Savarese G, Musella F, Volpe M, et al. Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis. Int J Cardiol 2013; 167 (6): 2482-9. DOI: 10.1016/j.ijcard.2012.05.010.
113. Dohi T, Miyauchi K, Okazaki S, et al. Long-term impact of mild chronic kidney disease in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Nephrol Dial Transplant. 2011; 26 (9): 2906-11. DOI: 10.1093/ndt/gfq820.
114. Shepherd J, Kastelein JJ, Bittner V, et al. TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008; 51 (15): 1448-54. DOI: 10.1016/j.jacc.2007.11.072.
115. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388 (10059): 2532-61. DOI: 10.1016/S01406736(16)31357-5.
116. Newman C, Tsai J, Szarek M, et al. Comparative Safety of Atorvasatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14236 patients. Am J Cardiology 2006; 97: 61-7. DOI: 10.1016/j.amjcard.2005.07.108.
117. Li H, Wang C, Zhang S, et al. Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants. Drug Saf. 2016; 39 (5): 409-19. DOI: 10.1007/s40264-016-0394-0.
118. Guglielmi V, Bellia A, Pecchioli S, et al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. Atherosclerosis. 2017; 263: 36-41. DOI: 10.1016/j.atherosclerosis.2017.05.018.
Рецензия
Для цитирования:
Гоголашвили Н.Г. АТОРВАСТАТИН — 20 ЛЕТ В БОРЬБЕ ЗА ЖИЗНЬ. Российский кардиологический журнал. 2018;(2):134-149. https://doi.org/10.15829/1560-4071-2018-2-134-149
For citation:
Gogolashvili N.G. ATORVASTATIN — 20 YEARS IN THE STRUGGLE FOR LIFE. Russian Journal of Cardiology. 2018;(2):134-149. (In Russ.) https://doi.org/10.15829/1560-4071-2018-2-134-149
Просмотров:
1155
Послать статью по эл. почте 